Navigation Links
BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA
Date:7/15/2009

PRINCETON, N.J., July 15 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into a license agreement with Merck KGaA, Darmstadt, Germany, providing the global healthcare and chemicals company with access to BioWa's POTELLIGENT((R)) Technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC).

"We are extremely pleased about our partnership with Merck KGaA, a global healthcare company with a strong worldwide presence," commented Dr. Masamichi Koike, BioWa's President and CEO. "Merck KGaA's world-class R&D organization and global market presence will enable us to promote and extend the benefit of the technology to patients all over the world more efficiently."

Under the terms of the license agreement, BioWa grants Merck KGaA non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT((R)) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other details of the agreement are not disclosed.

About POTELLIGENT((R)) Technology

POTELLIGENT((R)) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT((R)) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT((R)) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT((R)) antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab((TM)) platform. AccretaMab((TM)) platform consists of POTELLIGENT((R)) and COMPLEGENT((TM)) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT((R)) and COMPLEGENT((TM)) Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at www.biowa.com.

POTELLIGENT((R)), COMPLEGENT((TM)), and AccretaMab((TM)) are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.


'/>"/>
SOURCE BioWa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
2. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
3. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
4. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
5. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
6. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... March 20, 2017 , ... ... interfere with the ability of endogenous hormones to regulate homeostasis via their ... activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and immunological disorders. EDC ...
(Date:3/20/2017)... CA (PRWEB) , ... March 20, 2017 , ... ... require expensive and laborious sample preparation methods in order to reduce the impact ... underappreciated outside of the area of elemental analysis. , This presentation will ...
(Date:3/20/2017)... Clara, CA (PRWEB) , ... March 20, 2017 , ... ... free AFM Demo on Friday, March 24, 2017 from 5-7pm at their ... demo, and a special presentation from imec Senior Researcher, Dr. Tae-Gon Kim. , Dr. ...
(Date:3/20/2017)...  Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating ... or the "Company") (NYSE: BIOA ). Such investors ... by visiting the firm,s site: www.bgandg.com/bioa . ... officers and/or directors have violated Sections 10(b) and 20(a) of ... ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has ... World Lung Imaging Workshop at the University of Pennsylvania. ... invited to deliver the latest data to world leaders ... event brings together leaders at the forefront of the ... lung imaging. "The quality of the ...
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
Breaking Biology News(10 mins):